Yahoo · Aug 17, 2026
Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom
Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.
NASDAQ · CAPR
Capricor Therapeutics, Inc.
Healthcare · Biotechnology
$6.29
Down-$0.55 (-7.97%)
Updated Aug 22, 2026, 3:46 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.24B
- P/E ratio
- -17.75
- Dividend yield
- 0.00%
- 52-week range
- $2.96 – $40.37
- Volume
- 8.36M
- Avg. volume
- 2.79M
Price performance
CAPR price history
1M range · 20 trading sessions · Daily adjusted prices
CAPR closed at $6.29 after 20 trading sessions, down 68.07% for the selected period.
- Last close
- $6.29
- Period change
- -68.07%
- Period low
- $3.85
- Period high
- $19.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $6.81 | $7.08 | $6.01 | $6.29 | 8.36M |
| Aug 20, 2026 | $7.66 | $7.82 | $6.83 | $6.835 | 8.11M |
| Aug 19, 2026 | $7.19 | $7.99 | $7.14 | $7.98 | 8.57M |
| Aug 18, 2026 | $7.50 | $8.29 | $6.7641 | $7.08 | 8.54M |
| Aug 17, 2026 | $6.87 | $7.59 | $6.59 | $7.45 | 19.22M |
| Aug 14, 2026 | $7.66 | $8.15 | $6.04 | $6.65 | 66.33M |
| Aug 13, 2026 | $4.18 | $4.42 | $4.14 | $4.21 | 16.75M |
| Aug 12, 2026 | $3.95 | $4.30 | $3.90 | $4.19 | 2.75M |
| Aug 11, 2026 | $3.85 | $3.998 | $3.73 | $3.93 | 3.33M |
| Aug 10, 2026 | $4.04 | $4.105 | $3.805 | $3.85 | 3.09M |
| Aug 7, 2026 | $4.16 | $4.70 | $4.05 | $4.09 | 3.62M |
| Aug 6, 2026 | $3.88 | $4.21 | $3.8681 | $4.18 | 3.21M |
| Aug 5, 2026 | $4.16 | $4.31 | $3.845 | $3.93 | 3.68M |
| Aug 4, 2026 | $4.132 | $4.42 | $4.09 | $4.17 | 4.22M |
| Aug 3, 2026 | $3.775 | $4.20 | $3.658 | $4.20 | 5.17M |
| Jul 31, 2026 | $4.04 | $4.66 | $3.80 | $3.85 | 7.3M |
| Jul 30, 2026 | $3.07 | $4.21 | $2.96 | $4.19 | 28.92M |
| Jul 28, 2026 | $6.78 | $7.22 | $5.6652 | $6.57 | 16.55M |
| Jul 27, 2026 | $5.865 | $7.85 | $5.82 | $6.995 | 30M |
| Jul 24, 2026 | $19.7731 | $20.1792 | $18.305 | $19.70 | 2.47M |
Latest CAPR news
The latest Smart Investors Daily articles mentioning CAPR.
Stock researchCompany · Overview
CAPR research
Overview
Company profile and research snapshot.
Company profile
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $45.00
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | Jones Trading | Hold | — |
| Jul 30, 2026 | Piper Sandler | Neutral | — |
| Jul 30, 2026 | Cantor Fitzgerald | Neutral | — |
| Jul 30, 2026 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 16, 2026
Capricor Therapeutics (CAPR) Faces Class Action Scrutiny, Is The 88% Undervalued Case Credible?
Capricor Therapeutics (CAPR) is back in focus after two securities class action lawsuits accused the company of failing to disclose FDA concerns about changes to the statistical analysis plan for its lead drug candidate, Deramiocel. See our latest analysis for Capricor Therapeutics. The lawsuits arrive after a difficult stretch for Capricor Therapeutics, with the share price falling 76.5% year to date and 76.3% over 90 days, even though the stock has a 5 year total shareholder return of...
Yahoo · Aug 15, 2026
Capricor Therapeutics (CAPR) Is Up 62.6% After Mounting Deramiocel FDA Scrutiny And Lawsuits - What's Changed
In the past week, Capricor Therapeutics reported Q2 2026 results showing a net loss of US$40.73 million and higher per-share losses, while also facing growing legal and regulatory scrutiny over its lead Duchenne muscular dystrophy candidate, Deramiocel. The combination of widening losses and class action lawsuits alleging inadequate disclosure of FDA-related concerns around Deramiocel’s statistical analysis plan has intensified questions about the company’s transparency and regulatory risk...
SeekingAlpha · Aug 14, 2026
Capricor: Stock Now Surging On Fresh BLA Updates - What Investors Must Know
Capricor Therapeutics, Inc. stock jumps 75% on FDA talks for deramiocel in Duchenne cardiomyopathy. Click for this updated look at CAPR stock prospects.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
